Cognito Therapeutics Analysis: $423M Raised
What is Cognito Therapeutics?
Non-invasive neuromodulation therapy for Alzheimer’s with FDA Breakthrough Device Designation
Location
Cambridge, United States
Employees
51-200
Founded
2016
Product Features & Capabilities
- Neuromodulation therapy evoking gamma wave activity via visual and auditory stimulation
- Non-invasive home-based treatment for one hour daily
- FDA Breakthrough Device Designation for Alzheimer’s disease
Use Cases
Preserve brain volume in Alzheimer’s patients through daily home treatment; Slow cognitive and functional decline in early-stage Alzheimer’s; Maintain daily function in patients with mild cognitive impairment; Treat patients with abnormal gamma wave activity; Expand to other neurodegenerative diseases
Other Considerations
Received FDA Breakthrough Device Designation for Alzheimer’s; Showed significant slowing of disease progression in OVERTURE feasibility study; Expanding to other neurodegenerative diseases; Published at AAIC25; Featured in Bloomberg and Nasdaq interviews; Active clinical study pipeline with HOPE study ongoing
